| Ad Title: |
Endometrial Cancer |
| Study Title: |
GOG-209: A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer |
| Protocol Number: |
012004-007 |
| Department(s) involved in the Study: |
Gynecology, Obstetrics & Gynecology, Simmons Comprehensive Cancer Center
|
| Purpose of the Study: |
This study is being done on women who have cancer of the endometrium that cannot be cured with surgery or radiation therapy. Current treatment is a three-drug combination chemotherapy. This trial will compare the three-drug chemotherapy to a 2-drug combination chemotherapy. |
| Participant Eligibility: |
Patients must have Stage III or Stage IV or recurrent endometrial cancer. |
| Disease/Condition Under Study: |
Endometrial Cancer |
| Cancer Related Study: |
Yes
|
| Study Drug(s): |
|
| Study Device(s): |
|
| Study Doctor: |
Dr. David Miller |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Parkland Memorial Hospital
|
Yes
|
|
| Contact Phone: |
214_648_6753 |
| Email: |
Paula.Honea@utsouthwestern.edu |
| Other Information: |
This a Gynecologis Oncology Group sponsored trial. |
| Website Keywords: |
Gyn Oncology, Gynecology, Women's Health
|
| Medical Keywords: |
Cancer
|
